New Local Pharmaceutical Plant Expected To Enhance Access To Drugs In Kenya 12/01/2018 Justus Wanzala Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 Kenya’s pharmaceutical products manufacturing sector is hopeful it will experience significant growth after the Square Pharmaceuticals ltd (SPL) of Bangladesh commissioned a US$ 75 million plant in the East African nation this week. [A reminder: this story, like all of our stories, is completely free for almost every developing country in the world. Just sign up for a free password here!]Continue reading -> WTO Stalemate Concerns Include Non-Violation Complaints, E-Commerce; TRIPS Health Amendment Extended 08/01/2018 Monika Ermert Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 A few weeks after the failure of the World Trade Organization ministerial meeting in Buenos Aires to cut deals advancing issues from fisheries to e-commerce, some governments and trade experts around the world are concerned about the WTO’s future. Meanwhile, a couple of intellectual property-related provisions moved ahead after the ministerial without change. Continue reading -> Medicines Patent Pool Launches Search For Next Director 08/01/2018 William New Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 A negotiator and fundraiser with extensive experience with the pharmaceutical industry. Those are some of the qualities the next Medicines Patent Pool executive director might have, according to a just-posted job announcement. Continue reading -> A Canadian Billionaire’s Mysterious Death And The Effect On Access To Medicines 20/12/2017 William New Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 The mysterious death last week of Canadian billionaire Barry Sherman and his wife has raised many questions. For some, one question is what impact it will have on pharmaceutical competition in Canada, as his giant generic medicines company Apotex was seen as making a mark in access to medicines. It was also recalled that the company is the only one to have used an obscure provision of a World Trade Organization intellectual property agreement aimed at making more affordable medicines available in least developed countries. Continue reading -> G-Finder Report: Global Funding For R&D In Neglected Diseases Increasing, Overreliance On US Funding Dangerous 13/12/2017 Catherine Saez Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 A report released today on global funding of research and development for neglected diseases found that global funding has increased but warns that overreliance on funding from the United States, which the report says is “unparalleled,” and leads to a heavy concentration of global funding on HIV/AIDS, malaria and tuberculosis. This overreliance could also lead to change in total global funding, the report found. Continue reading -> Patents And Health Under Discussion At WIPO This Week: What Role For The UN IP Agency? 12/12/2017 Catherine Saez Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 Patents are often involved in public health policy discussions, and are considered by some as playing a major role in the escalating prices of new medicines, creating access issues. The World Intellectual Property Organization committee on patent law this week is discussing the issue and is holding information sessions by the Medicines Patent Pool, World Health Organization, and the World Trade Organization. Continue reading -> Medicines Patent Pool Expands Its Patent Database To Cancer Treatments 12/12/2017 Catherine Saez By Catherine Saez The Medicines Patent Pool (MPP) announced today that MedsPaL, its database of information on the patent and licensing status of selected HIV, hepatitis C, and tuberculosis medicines, now extends to patented treatments on the World Health Organization Model List of Essential Medicines. New patents data include medicines for leukaemia, breast cancer and other cancer indications. Continue reading -> Analysis: As Biosimilar Of Key Cancer Drug Spreads, Where Is The Price Reduction? 11/12/2017 Tatum Anderson Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 The first biosimilar of the blockbuster breast cancer drug trastuzumab is being prepared for launch in United States, following a decision by the Food and Drug Administration (FDA) to approve it earlier this month. The product, Ogivri, has been created by a joint venture between US Mylan and Indian company Biocon. Continue reading -> New UNCTAD, GIZ Toolbox: How To Achieve Policy Coherence For Local Production And Access To Medicines 05/12/2017 Guest contributor Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 What do investment, trade, intellectual property, health financing, R&D, industrial and medicines regulation policy have in common? They are all important building blocks for the successful promotion of local pharmaceutical manufacturing. As more and more countries are looking into building their own pharmaceutical production capacities, they need to ensure strong policy coherence to be successful. Continue reading -> Global Biotech Industry Tests Policy Waters In Geneva 04/12/2017 Catherine Saez Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 A delegation of heads of biotechnology companies visited Geneva this month to present the International Confederation of Biotechnology Trade Associations (ICBA). The ICBA was created in 2012, but is now looking to make its voice heard in Geneva and inform policy discussions, and is finding it is not easy to become an observer in some organisations. They also underlined the importance of intellectual property for the biotech sector, in particular to attract indispensable capital. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
WTO Stalemate Concerns Include Non-Violation Complaints, E-Commerce; TRIPS Health Amendment Extended 08/01/2018 Monika Ermert Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 A few weeks after the failure of the World Trade Organization ministerial meeting in Buenos Aires to cut deals advancing issues from fisheries to e-commerce, some governments and trade experts around the world are concerned about the WTO’s future. Meanwhile, a couple of intellectual property-related provisions moved ahead after the ministerial without change. Continue reading -> Medicines Patent Pool Launches Search For Next Director 08/01/2018 William New Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 A negotiator and fundraiser with extensive experience with the pharmaceutical industry. Those are some of the qualities the next Medicines Patent Pool executive director might have, according to a just-posted job announcement. Continue reading -> A Canadian Billionaire’s Mysterious Death And The Effect On Access To Medicines 20/12/2017 William New Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 The mysterious death last week of Canadian billionaire Barry Sherman and his wife has raised many questions. For some, one question is what impact it will have on pharmaceutical competition in Canada, as his giant generic medicines company Apotex was seen as making a mark in access to medicines. It was also recalled that the company is the only one to have used an obscure provision of a World Trade Organization intellectual property agreement aimed at making more affordable medicines available in least developed countries. Continue reading -> G-Finder Report: Global Funding For R&D In Neglected Diseases Increasing, Overreliance On US Funding Dangerous 13/12/2017 Catherine Saez Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 A report released today on global funding of research and development for neglected diseases found that global funding has increased but warns that overreliance on funding from the United States, which the report says is “unparalleled,” and leads to a heavy concentration of global funding on HIV/AIDS, malaria and tuberculosis. This overreliance could also lead to change in total global funding, the report found. Continue reading -> Patents And Health Under Discussion At WIPO This Week: What Role For The UN IP Agency? 12/12/2017 Catherine Saez Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 Patents are often involved in public health policy discussions, and are considered by some as playing a major role in the escalating prices of new medicines, creating access issues. The World Intellectual Property Organization committee on patent law this week is discussing the issue and is holding information sessions by the Medicines Patent Pool, World Health Organization, and the World Trade Organization. Continue reading -> Medicines Patent Pool Expands Its Patent Database To Cancer Treatments 12/12/2017 Catherine Saez By Catherine Saez The Medicines Patent Pool (MPP) announced today that MedsPaL, its database of information on the patent and licensing status of selected HIV, hepatitis C, and tuberculosis medicines, now extends to patented treatments on the World Health Organization Model List of Essential Medicines. New patents data include medicines for leukaemia, breast cancer and other cancer indications. Continue reading -> Analysis: As Biosimilar Of Key Cancer Drug Spreads, Where Is The Price Reduction? 11/12/2017 Tatum Anderson Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 The first biosimilar of the blockbuster breast cancer drug trastuzumab is being prepared for launch in United States, following a decision by the Food and Drug Administration (FDA) to approve it earlier this month. The product, Ogivri, has been created by a joint venture between US Mylan and Indian company Biocon. Continue reading -> New UNCTAD, GIZ Toolbox: How To Achieve Policy Coherence For Local Production And Access To Medicines 05/12/2017 Guest contributor Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 What do investment, trade, intellectual property, health financing, R&D, industrial and medicines regulation policy have in common? They are all important building blocks for the successful promotion of local pharmaceutical manufacturing. As more and more countries are looking into building their own pharmaceutical production capacities, they need to ensure strong policy coherence to be successful. Continue reading -> Global Biotech Industry Tests Policy Waters In Geneva 04/12/2017 Catherine Saez Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 A delegation of heads of biotechnology companies visited Geneva this month to present the International Confederation of Biotechnology Trade Associations (ICBA). The ICBA was created in 2012, but is now looking to make its voice heard in Geneva and inform policy discussions, and is finding it is not easy to become an observer in some organisations. They also underlined the importance of intellectual property for the biotech sector, in particular to attract indispensable capital. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Medicines Patent Pool Launches Search For Next Director 08/01/2018 William New Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 A negotiator and fundraiser with extensive experience with the pharmaceutical industry. Those are some of the qualities the next Medicines Patent Pool executive director might have, according to a just-posted job announcement. Continue reading -> A Canadian Billionaire’s Mysterious Death And The Effect On Access To Medicines 20/12/2017 William New Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 The mysterious death last week of Canadian billionaire Barry Sherman and his wife has raised many questions. For some, one question is what impact it will have on pharmaceutical competition in Canada, as his giant generic medicines company Apotex was seen as making a mark in access to medicines. It was also recalled that the company is the only one to have used an obscure provision of a World Trade Organization intellectual property agreement aimed at making more affordable medicines available in least developed countries. Continue reading -> G-Finder Report: Global Funding For R&D In Neglected Diseases Increasing, Overreliance On US Funding Dangerous 13/12/2017 Catherine Saez Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 A report released today on global funding of research and development for neglected diseases found that global funding has increased but warns that overreliance on funding from the United States, which the report says is “unparalleled,” and leads to a heavy concentration of global funding on HIV/AIDS, malaria and tuberculosis. This overreliance could also lead to change in total global funding, the report found. Continue reading -> Patents And Health Under Discussion At WIPO This Week: What Role For The UN IP Agency? 12/12/2017 Catherine Saez Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 Patents are often involved in public health policy discussions, and are considered by some as playing a major role in the escalating prices of new medicines, creating access issues. The World Intellectual Property Organization committee on patent law this week is discussing the issue and is holding information sessions by the Medicines Patent Pool, World Health Organization, and the World Trade Organization. Continue reading -> Medicines Patent Pool Expands Its Patent Database To Cancer Treatments 12/12/2017 Catherine Saez By Catherine Saez The Medicines Patent Pool (MPP) announced today that MedsPaL, its database of information on the patent and licensing status of selected HIV, hepatitis C, and tuberculosis medicines, now extends to patented treatments on the World Health Organization Model List of Essential Medicines. New patents data include medicines for leukaemia, breast cancer and other cancer indications. Continue reading -> Analysis: As Biosimilar Of Key Cancer Drug Spreads, Where Is The Price Reduction? 11/12/2017 Tatum Anderson Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 The first biosimilar of the blockbuster breast cancer drug trastuzumab is being prepared for launch in United States, following a decision by the Food and Drug Administration (FDA) to approve it earlier this month. The product, Ogivri, has been created by a joint venture between US Mylan and Indian company Biocon. Continue reading -> New UNCTAD, GIZ Toolbox: How To Achieve Policy Coherence For Local Production And Access To Medicines 05/12/2017 Guest contributor Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 What do investment, trade, intellectual property, health financing, R&D, industrial and medicines regulation policy have in common? They are all important building blocks for the successful promotion of local pharmaceutical manufacturing. As more and more countries are looking into building their own pharmaceutical production capacities, they need to ensure strong policy coherence to be successful. Continue reading -> Global Biotech Industry Tests Policy Waters In Geneva 04/12/2017 Catherine Saez Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 A delegation of heads of biotechnology companies visited Geneva this month to present the International Confederation of Biotechnology Trade Associations (ICBA). The ICBA was created in 2012, but is now looking to make its voice heard in Geneva and inform policy discussions, and is finding it is not easy to become an observer in some organisations. They also underlined the importance of intellectual property for the biotech sector, in particular to attract indispensable capital. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
A Canadian Billionaire’s Mysterious Death And The Effect On Access To Medicines 20/12/2017 William New Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 The mysterious death last week of Canadian billionaire Barry Sherman and his wife has raised many questions. For some, one question is what impact it will have on pharmaceutical competition in Canada, as his giant generic medicines company Apotex was seen as making a mark in access to medicines. It was also recalled that the company is the only one to have used an obscure provision of a World Trade Organization intellectual property agreement aimed at making more affordable medicines available in least developed countries. Continue reading -> G-Finder Report: Global Funding For R&D In Neglected Diseases Increasing, Overreliance On US Funding Dangerous 13/12/2017 Catherine Saez Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 A report released today on global funding of research and development for neglected diseases found that global funding has increased but warns that overreliance on funding from the United States, which the report says is “unparalleled,” and leads to a heavy concentration of global funding on HIV/AIDS, malaria and tuberculosis. This overreliance could also lead to change in total global funding, the report found. Continue reading -> Patents And Health Under Discussion At WIPO This Week: What Role For The UN IP Agency? 12/12/2017 Catherine Saez Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 Patents are often involved in public health policy discussions, and are considered by some as playing a major role in the escalating prices of new medicines, creating access issues. The World Intellectual Property Organization committee on patent law this week is discussing the issue and is holding information sessions by the Medicines Patent Pool, World Health Organization, and the World Trade Organization. Continue reading -> Medicines Patent Pool Expands Its Patent Database To Cancer Treatments 12/12/2017 Catherine Saez By Catherine Saez The Medicines Patent Pool (MPP) announced today that MedsPaL, its database of information on the patent and licensing status of selected HIV, hepatitis C, and tuberculosis medicines, now extends to patented treatments on the World Health Organization Model List of Essential Medicines. New patents data include medicines for leukaemia, breast cancer and other cancer indications. Continue reading -> Analysis: As Biosimilar Of Key Cancer Drug Spreads, Where Is The Price Reduction? 11/12/2017 Tatum Anderson Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 The first biosimilar of the blockbuster breast cancer drug trastuzumab is being prepared for launch in United States, following a decision by the Food and Drug Administration (FDA) to approve it earlier this month. The product, Ogivri, has been created by a joint venture between US Mylan and Indian company Biocon. Continue reading -> New UNCTAD, GIZ Toolbox: How To Achieve Policy Coherence For Local Production And Access To Medicines 05/12/2017 Guest contributor Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 What do investment, trade, intellectual property, health financing, R&D, industrial and medicines regulation policy have in common? They are all important building blocks for the successful promotion of local pharmaceutical manufacturing. As more and more countries are looking into building their own pharmaceutical production capacities, they need to ensure strong policy coherence to be successful. Continue reading -> Global Biotech Industry Tests Policy Waters In Geneva 04/12/2017 Catherine Saez Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 A delegation of heads of biotechnology companies visited Geneva this month to present the International Confederation of Biotechnology Trade Associations (ICBA). The ICBA was created in 2012, but is now looking to make its voice heard in Geneva and inform policy discussions, and is finding it is not easy to become an observer in some organisations. They also underlined the importance of intellectual property for the biotech sector, in particular to attract indispensable capital. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
G-Finder Report: Global Funding For R&D In Neglected Diseases Increasing, Overreliance On US Funding Dangerous 13/12/2017 Catherine Saez Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 A report released today on global funding of research and development for neglected diseases found that global funding has increased but warns that overreliance on funding from the United States, which the report says is “unparalleled,” and leads to a heavy concentration of global funding on HIV/AIDS, malaria and tuberculosis. This overreliance could also lead to change in total global funding, the report found. Continue reading -> Patents And Health Under Discussion At WIPO This Week: What Role For The UN IP Agency? 12/12/2017 Catherine Saez Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 Patents are often involved in public health policy discussions, and are considered by some as playing a major role in the escalating prices of new medicines, creating access issues. The World Intellectual Property Organization committee on patent law this week is discussing the issue and is holding information sessions by the Medicines Patent Pool, World Health Organization, and the World Trade Organization. Continue reading -> Medicines Patent Pool Expands Its Patent Database To Cancer Treatments 12/12/2017 Catherine Saez By Catherine Saez The Medicines Patent Pool (MPP) announced today that MedsPaL, its database of information on the patent and licensing status of selected HIV, hepatitis C, and tuberculosis medicines, now extends to patented treatments on the World Health Organization Model List of Essential Medicines. New patents data include medicines for leukaemia, breast cancer and other cancer indications. Continue reading -> Analysis: As Biosimilar Of Key Cancer Drug Spreads, Where Is The Price Reduction? 11/12/2017 Tatum Anderson Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 The first biosimilar of the blockbuster breast cancer drug trastuzumab is being prepared for launch in United States, following a decision by the Food and Drug Administration (FDA) to approve it earlier this month. The product, Ogivri, has been created by a joint venture between US Mylan and Indian company Biocon. Continue reading -> New UNCTAD, GIZ Toolbox: How To Achieve Policy Coherence For Local Production And Access To Medicines 05/12/2017 Guest contributor Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 What do investment, trade, intellectual property, health financing, R&D, industrial and medicines regulation policy have in common? They are all important building blocks for the successful promotion of local pharmaceutical manufacturing. As more and more countries are looking into building their own pharmaceutical production capacities, they need to ensure strong policy coherence to be successful. Continue reading -> Global Biotech Industry Tests Policy Waters In Geneva 04/12/2017 Catherine Saez Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 A delegation of heads of biotechnology companies visited Geneva this month to present the International Confederation of Biotechnology Trade Associations (ICBA). The ICBA was created in 2012, but is now looking to make its voice heard in Geneva and inform policy discussions, and is finding it is not easy to become an observer in some organisations. They also underlined the importance of intellectual property for the biotech sector, in particular to attract indispensable capital. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Patents And Health Under Discussion At WIPO This Week: What Role For The UN IP Agency? 12/12/2017 Catherine Saez Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 Patents are often involved in public health policy discussions, and are considered by some as playing a major role in the escalating prices of new medicines, creating access issues. The World Intellectual Property Organization committee on patent law this week is discussing the issue and is holding information sessions by the Medicines Patent Pool, World Health Organization, and the World Trade Organization. Continue reading -> Medicines Patent Pool Expands Its Patent Database To Cancer Treatments 12/12/2017 Catherine Saez By Catherine Saez The Medicines Patent Pool (MPP) announced today that MedsPaL, its database of information on the patent and licensing status of selected HIV, hepatitis C, and tuberculosis medicines, now extends to patented treatments on the World Health Organization Model List of Essential Medicines. New patents data include medicines for leukaemia, breast cancer and other cancer indications. Continue reading -> Analysis: As Biosimilar Of Key Cancer Drug Spreads, Where Is The Price Reduction? 11/12/2017 Tatum Anderson Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 The first biosimilar of the blockbuster breast cancer drug trastuzumab is being prepared for launch in United States, following a decision by the Food and Drug Administration (FDA) to approve it earlier this month. The product, Ogivri, has been created by a joint venture between US Mylan and Indian company Biocon. Continue reading -> New UNCTAD, GIZ Toolbox: How To Achieve Policy Coherence For Local Production And Access To Medicines 05/12/2017 Guest contributor Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 What do investment, trade, intellectual property, health financing, R&D, industrial and medicines regulation policy have in common? They are all important building blocks for the successful promotion of local pharmaceutical manufacturing. As more and more countries are looking into building their own pharmaceutical production capacities, they need to ensure strong policy coherence to be successful. Continue reading -> Global Biotech Industry Tests Policy Waters In Geneva 04/12/2017 Catherine Saez Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 A delegation of heads of biotechnology companies visited Geneva this month to present the International Confederation of Biotechnology Trade Associations (ICBA). The ICBA was created in 2012, but is now looking to make its voice heard in Geneva and inform policy discussions, and is finding it is not easy to become an observer in some organisations. They also underlined the importance of intellectual property for the biotech sector, in particular to attract indispensable capital. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Medicines Patent Pool Expands Its Patent Database To Cancer Treatments 12/12/2017 Catherine Saez By Catherine Saez The Medicines Patent Pool (MPP) announced today that MedsPaL, its database of information on the patent and licensing status of selected HIV, hepatitis C, and tuberculosis medicines, now extends to patented treatments on the World Health Organization Model List of Essential Medicines. New patents data include medicines for leukaemia, breast cancer and other cancer indications. Continue reading -> Analysis: As Biosimilar Of Key Cancer Drug Spreads, Where Is The Price Reduction? 11/12/2017 Tatum Anderson Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 The first biosimilar of the blockbuster breast cancer drug trastuzumab is being prepared for launch in United States, following a decision by the Food and Drug Administration (FDA) to approve it earlier this month. The product, Ogivri, has been created by a joint venture between US Mylan and Indian company Biocon. Continue reading -> New UNCTAD, GIZ Toolbox: How To Achieve Policy Coherence For Local Production And Access To Medicines 05/12/2017 Guest contributor Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 What do investment, trade, intellectual property, health financing, R&D, industrial and medicines regulation policy have in common? They are all important building blocks for the successful promotion of local pharmaceutical manufacturing. As more and more countries are looking into building their own pharmaceutical production capacities, they need to ensure strong policy coherence to be successful. Continue reading -> Global Biotech Industry Tests Policy Waters In Geneva 04/12/2017 Catherine Saez Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 A delegation of heads of biotechnology companies visited Geneva this month to present the International Confederation of Biotechnology Trade Associations (ICBA). The ICBA was created in 2012, but is now looking to make its voice heard in Geneva and inform policy discussions, and is finding it is not easy to become an observer in some organisations. They also underlined the importance of intellectual property for the biotech sector, in particular to attract indispensable capital. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Analysis: As Biosimilar Of Key Cancer Drug Spreads, Where Is The Price Reduction? 11/12/2017 Tatum Anderson Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 The first biosimilar of the blockbuster breast cancer drug trastuzumab is being prepared for launch in United States, following a decision by the Food and Drug Administration (FDA) to approve it earlier this month. The product, Ogivri, has been created by a joint venture between US Mylan and Indian company Biocon. Continue reading -> New UNCTAD, GIZ Toolbox: How To Achieve Policy Coherence For Local Production And Access To Medicines 05/12/2017 Guest contributor Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 What do investment, trade, intellectual property, health financing, R&D, industrial and medicines regulation policy have in common? They are all important building blocks for the successful promotion of local pharmaceutical manufacturing. As more and more countries are looking into building their own pharmaceutical production capacities, they need to ensure strong policy coherence to be successful. Continue reading -> Global Biotech Industry Tests Policy Waters In Geneva 04/12/2017 Catherine Saez Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 A delegation of heads of biotechnology companies visited Geneva this month to present the International Confederation of Biotechnology Trade Associations (ICBA). The ICBA was created in 2012, but is now looking to make its voice heard in Geneva and inform policy discussions, and is finding it is not easy to become an observer in some organisations. They also underlined the importance of intellectual property for the biotech sector, in particular to attract indispensable capital. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
New UNCTAD, GIZ Toolbox: How To Achieve Policy Coherence For Local Production And Access To Medicines 05/12/2017 Guest contributor Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 What do investment, trade, intellectual property, health financing, R&D, industrial and medicines regulation policy have in common? They are all important building blocks for the successful promotion of local pharmaceutical manufacturing. As more and more countries are looking into building their own pharmaceutical production capacities, they need to ensure strong policy coherence to be successful. Continue reading -> Global Biotech Industry Tests Policy Waters In Geneva 04/12/2017 Catherine Saez Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 A delegation of heads of biotechnology companies visited Geneva this month to present the International Confederation of Biotechnology Trade Associations (ICBA). The ICBA was created in 2012, but is now looking to make its voice heard in Geneva and inform policy discussions, and is finding it is not easy to become an observer in some organisations. They also underlined the importance of intellectual property for the biotech sector, in particular to attract indispensable capital. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Global Biotech Industry Tests Policy Waters In Geneva 04/12/2017 Catherine Saez Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 A delegation of heads of biotechnology companies visited Geneva this month to present the International Confederation of Biotechnology Trade Associations (ICBA). The ICBA was created in 2012, but is now looking to make its voice heard in Geneva and inform policy discussions, and is finding it is not easy to become an observer in some organisations. They also underlined the importance of intellectual property for the biotech sector, in particular to attract indispensable capital. Continue reading -> Posts navigation Older postsNewer posts